drugset / Trial / NCT00006371
A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
Phase 2
Terminated
2 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Janssen Pharmaceuticals · collabNational Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
Timeline
- Start
- 2000-05
- Primary completion
- 2001-12
- Completion
- 2001-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aminoglutethimide | Small molecule | — | Oral |
| Comparator | Hydrocortisone | Other / unclassified | — | Oral |
| Comparator | Ketoconazole | Small molecule | — | Oral |